Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|December 11, 2025
Amphiphilic Poly(N-vinylpyrrolidone) Biocomposites with Bortezomib and DR5-Selective TRAIL Variants: A Promising Approach to Pancreatic Cancer TreatmentEkaterina Kukovyakina, Alina A Isakova, Dmitry Bagrov, et al.
International Journal of Molecular Sciences|June 10, 2022
Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor SpecificityAnne V Yagolovich, Artem A Artykov, Alina A Isakova, et al.
Biochemistry. Biokhimiia|November 10, 2024
Glioblastoma Sensitization to Therapeutic Effects by Glutamine Deprivation Depends on Cellular Phenotype and MetabolismAlina A Isakova, Irina N Druzhkova, Artem M Mozherov, et al.
Biochemistry. Biokhimiia|October 9, 2025
Novel Fusion Protein Based on DR5-Specific TRAIL Variant with Enhanced Antitumor PropertiesAnne V Yagolovich, Alina A Isakova, Ekaterina V Kukovyakina, et al.
Medical Oncology (Northwood, London, England)|November 17, 2025
Temozolomide-induced senescent glioblastoma cells acquire sensitivity to TRAIL death receptor 5-mediated apoptosisAlina A Isakova, Diana V Mazur, Nadezhda V Antipova, et al.
ACS Applied Bio Materials|November 24, 2025
Codelivery of Bortezomib and Modified DR5-Selective TRAIL via Amphiphilic Poly(N-vinylpyrrolidone) Bionanocomposites to Overcome Glioblastoma ResistanceEkaterina V Kukovyakina, Pavel P Kulikov, Dmitry V Bagrov, et al.
International Journal of Biological Macromolecules|November 16, 2023
Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesisAlina A Isakova, Artem A Artykov, Ekaterina A Plotnikova, et al.
Biomedical Reports|February 12, 2024
Assessment of the effects of amphiphilic poly (N‑vinylpyrrolidone) nanoparticles loaded with bortezomib on glioblastoma cell lines and zebrafish embryosAnne V Yagolovich, Andrey N Kuskov, Pavel P Kulikov, et al.
International Journal of Molecular Sciences|May 25, 2024
Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687Anne V Yagolovich, Alina A Isakova, Artem A Artykov, et al.
International Journal of Molecular Sciences|October 27, 2022
DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against GlioblastomaAnne V Yagolovich, Alina A Isakova, Artem A Artykov, et al.
Pageof 2